JohnJosephNemunaitisMD

Oncology • Toledo, OH

Physician

Join to view full profile

Are you Dr. Nemunaitis?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 71 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1325 Conference Dr
Toledo, OH 43614
Phone+1 419-383-6644

Fax+1 419-383-3339
Is this information wrong?

Summary

Dr. John Nemunaitis, MD is an oncologist in Toledo, Ohio. He is currently licensed to practice medicine in Ohio, Texas, and Pennsylvania. He is affiliated with The University of Toledo Medical Center.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1985 - 1988
Boston University Medical CenterResidency, Internal Medicine, 1984 - 1985
Boston University Medical CenterInternship, Internal Medicine, 1982 - 1983
Case Western Reserve University School of MedicineClass of 1982

Certifications & Licensure

OH State Medical License 2017 - 2026
TX State Medical License 1993 - 2025
PA State Medical License 1991 - 1994
WA State Medical License 1985 - 1992
American Board of Internal Medicine Internal Medicine

Clinical Trials

Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
Unknown status
Phase 3
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
Unknown status
Phase 3
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer Start of enrollment: 2003 May 01
Unknown status
Phase 1
Safety Study of Infusion of SGT-53 to Treat Solid Tumors Start of enrollment: 2008 Feb 01
Completed
Phase 1
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions Start of enrollment: 2009 Aug 01
Completed
Phase 1
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies Start of enrollment: 2009 Dec 01
Completed
Phase 1
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2, Phase 3
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01
Completed
Phase 1
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer Start of enrollment: 2012 May 01
Completed
Phase 1
Phase 1 Study of ONT-10 in Patients With Solid Tumors Start of enrollment: 2013 Mar 01
Completed
Phase 1
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors Start of enrollment: 2012 Sep 01
Suspended
Phase 1, Phase 2
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) Start of enrollment: 2012 Jul 03
Completed
Phase 2
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Start of enrollment: 2012 Dec 01
Completed
Phase 2
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma Start of enrollment: 2013 Jan 01
Completed
Phase 2
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Start of enrollment: 2013 Dec 31
Completed
Phase 1
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2014 Jul 01
Terminated
Phase 2
RTA 408 Capsules in Patients With Melanoma - REVEAL Start of enrollment: 2014 Oct 31
Completed
Phase 1, Phase 2
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure Start of enrollment: 2016 Feb 12
Terminated
Phase 3
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer Start of enrollment: 2017 Mar 23
Terminated
Phase 1
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors Start of enrollment: 2019 Jun 05
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Peter Anderson, Maurizio Ghisoli, Brian D Crompton, Kelly S Klega, Leonard H Wexler, Emily K Slotkin, Laura Stanbery, Luisa Manning, Gladice Wallraven, Meghan Manley, ...> ;Clinical Cancer Research. 2023 May 1
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncolog...
Rodney P Rocconi, Bradley J Monk, Adam Walter, Thomas J Herzog, Evanthia Galanis, Luisa Manning, Ernest Bognar, Gladice Wallraven, Laura Stanbery, Phylicia Aaron, Neil...> ;Gynecologic Oncology. 2023 Feb 1
6 citations
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase...
Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lanc...> ;Journal for Immunotherapy of Cancer. 2022 Mar 1
6 citations
Subclonal landscape of cancer drives resistance to immune therapy.
Daniel J Craig, Morgan M Bailey, Olivia B Noe, Kada K Williams, Laura Stanbery, Danae M Hamouda, John J Nemunaitis> ;Cancer Treatment and Research Communications. 2022 Jan 1
6 citations
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
Minal Barve, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven, Staci Horvath, Laura Stanbery, John Nemunaitis> ;Clinical Medicine Insights. Oncology. 2022 Jan 1
5 citations
Systemic benefit of radiation therapyabscopal effect.
Daniel J Craig, Stephanie Ambrose, Laura Stanbery, Adam Walter, John Nemunaitis> ;Frontiers in Oncology. 2022 Jan 1
12 citations
Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Matthew H. Taylor, Courtney Betts, Lauren Maloney, Eric Nadler, Alain Algazi, Michael J. Guarino, John Nemunaitis, Antonio Jimeno, Priti Patel, Veerendra Munugalavadla...> ;Clinical Cancer Research. 2021 Dec 3
4 citations
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
Elyssa Sliheet, Molly Robinson, Susan Morand, Khalil Choucair, David Willoughby, Laura Stanbery, Phylicia Aaron, Ernest Bognar, John Nemunaitis> ;Cancer Gene Therapy. 2021 Nov 16
34 citations
Homologous recombination proficiency in ovarian and breast cancer patients
Justin F. Creeden, Nisha S. Nanavaty, Cassidy Gillman, Laura Stanbery, Danae Hamouda, Lance D. Dworkin, John Nemunaitis> ;BMC Cancer. 2021 Oct 28
11 citations
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Adam Walter, Rodney P. Rocconi, Bradley J. Monk, Thomas J. Herzog, Luisa Manning, Ernest Bognar, Gladice Wallraven, Phylicia Aaron, Staci Horvath, Min Tang, Laura Stan...> ;Gynecologic Oncology. 2021 Oct 23
3 citations
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6.
Vedin Barve, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal A. Barve, John Nemunaitis> ;Vaccines. 2021 Oct 18
11 citations
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.
Apostolia Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire F. Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica M. Mita, Hae...> ;Journal of Hematology & Oncology. 2021 Aug 18
12 citations
Tumor suppressor immune gene therapy to reverse immunotherapy resistance.
Sunil Chada, Dora Wiederhold, Kerstin B. Menander, Beatha Sellman, Max Talbott, John Nemunaitis, Hyo Min Ahn, Bo-Kyeong Jung, Chae-Ok Yun, Robert E. Sobol> ;Cancer Gene Therapy. 2021 Aug 5
9 citations
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.
Rodney P. Rocconi, Laura Stanbery, Luciana Madeira da Silva, Robert A. Barrington, Phylicia Aaron, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Adam...> ;Vaccines. 2021 Aug 1
3 citations
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Michael S. Gordon, John Nemunaitis, Minal A. Barve, Zev A. Wainberg, Erika Hamilton, Ramesh K. Ramanathan, George W. Sledge, Huibin Yue, Susan E. Morgan-Lappe, Martha ...> ;Molecular Cancer Therapeutics. 2021 Jul 26
114 citations
Ovarian Cancer Immunotherapy and Personalized Medicine
Susan Morand, Monika Devanaboyina, Hannah Staats, Laura Stanbery, John Nemunaitis> ;International Journal of Molecular Sciences. 2021 Jun 18
6 citations
BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Rachel Royfman, Emma Whiteley, Olivia Noe, Susan Morand, Justin F. Creeden, Laura Stanbery, Danae Hamouda, John Nemunaitis> ;Future Oncology. 2021 Jun 1
16 citations
Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma.
Robert E. Sobol, Kerstin B. Menander, Sunil Chada, Dora Wiederhold, Beatha Sellman, Max Talbott, John Nemunaitis> ;Frontiers in Oncology. 2021 Apr 22
12 citations
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Rodney P. Rocconi, Erin E. Stevens, Justin N. Bottsford-Miller, Sharad A. Ghamande, Jeffrey Elder, Leslie L. DeMars, Adnan R. Munkarah, Phylicia Aaron, Laura Stanbery,...> ;Cancer Gene Therapy. 2021 Mar 22
50 citations
The abscopal effect of radiation therapy.
Daniel J Craig, Nisha S. Nanavaty, Monika Devanaboyina, Laura Stanbery, Danae Hamouda, Gerald Edelman, Lance D. Dworkin, John Nemunaitis> ;Future Oncology. 2021 Mar 17
18 citations
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rodney P. Rocconi, Bradley J. Monk, Adam Walter, Thomas J. Herzog, Evanthia Galanis, Luisa Manning, Ernest Bognar, Gladice Wallraven, Laura Stanbery, Phylicia Aaron, N...> ;Gynecologic Oncology. 2021 Mar 11
3 citations
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol....
Jonathan Oh, Minal A. Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaiti...> ;Gynecologic Oncology Reports. 2021 Mar 1
11 citations
Adenomatous polyposis coli in cancer and therapeutic implications.
Olivia Noe, Louis Filipiak, Rachel Royfman, Austin Campbell, Leslie L Lin, Danae Hamouda, Laura Stanbery, John Nemunaitis> ;Oncology Reviews. 2021 Feb 26
22 citations
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider, Jerome H. Goldschmidt, Jennifer L. Eisenstein, David Berz, Lasika Senevi...> ;Journal of Thoracic Oncology. 2021 Feb 1
31 citations
Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Vinaya Gogineni, Susan Morand, Hannah Staats, Rachel Royfman, Monika Devanaboyina, Danielle Dever, Laura Stanbery, Phylicia Aaron, Luisa Manning, Adam Walter, Gerald E...> ;Journal of Cancer. 2021 Jan 1
Join now to see all

Press Mentions

Immunotherapy Shows Promise for Difficult-to-Treat HRP Ovarian CancerDecember 1st, 2021
Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsOctober 17th, 2020
Health Care Research Benefits RegionApril 7th, 2020
Join now to see all

Hospital Affiliations

Medical City DallasDallas, Texas
The University of Toledo Medical CenterToledo, Ohio